Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I Pharmacokinetics and Tolerance of Anfibatide in Healthy Volunteers
NCT04404790Phase 1Suspended
- Sponsor
- Lee's Pharmaceutical Holdings Limited
- Start
- Sep 2020
- Primary completion
- Mar 2021
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, open-label trial of anfibatide in thrombotic thrombocytopenic purpura (TTP), ischemic stroke and myocardial infarction (MI) (8 arms), sponsored by Lee's Pharmaceutical Holdings Limited. Primary endpoint: Bleeding events at 7 days. Started Sep 2020; status: suspended.
02
Drugs
anfibatide
03
Conditions
thrombotic thrombocytopenic purpura (TTP)ischemic strokemyocardial infarction (MI)
Beyond the preview
Go deeper on NCT04404790.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04404790.